Literature DB >> 7929350

Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes.

J Weiss1, M Inada, P Elsbach, R M Crowl.   

Abstract

Extracellular 14-kDa phospholipases A2 (PLA2) in inflammatory exudates can contribute to bacterial phospholipid (PL) degradation during phagocytosis of Escherichia coli by polymorphonuclear leukocytes (PMN) and are highly active toward E. coli treated with the bactericidal/permeability-increasing protein (BPI) purified from PMN. PLA2 activity toward BPI-treated E. coli varies greatly among members of this conserved family of enzymes and apparently depends on a cluster of basic residues in a variable surface region near the NH2 terminus for recognition of this biological target (Weiss, J., Wright, G.W., Bekkers, A.C.A.P.A., van den Bergh, C.J., and Verheij, H.M. (1991) J. Biol. Chem. 266, 4162-4167). We have examined by site-specific mutagenesis of a recombinant PLA2 that is identical to an enzyme in human synovial fluid (containing His-6, Arg-7, Lys-10, and Lys-15 and a global net charge of +15) the role of basic residues in this region in PLA2 action against PLA-deficient (pldA-) E. coli. Substitution of Ser for Arg-7 +/- Gln for Lys-15 caused, respectively, about a 10- and 25-fold reduction in BPI-dependent PLA2 binding and activity to E. coli, but had no effect on hydrolysis of PL of autoclaved E. coli or dispersions of purified PL. PL degradation during phagocytosis was increased after pretreatment of E. coli (or PMN) with wild-type PLA2 followed by removal of unbound PLA2. Thus, the PLA2 binds to cells before phagocytosis followed by internalization of the enzyme along with E. coli and intracellular action. Mutant (e.g. R7S +/- K15Q) PLA2 show the same BPI-independent binding to E. coli as the wild-type enzyme but 10-30-fold reduced activity during phagocytosis, reflecting lower intracellular activity of these enzymes. Thus, structural determinants first implicated in PLA2 action toward E. coli treated with purified BPI apparently are also important in the intracellular action of PLA2 during phagocytosis by PMN.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929350

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli.

Authors:  L M Madsen; M Inada; J Weiss
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

Review 3.  Bacterial resistance mechanisms against host defense peptides.

Authors:  Tomaz Koprivnjak; Andreas Peschel
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

4.  Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears.

Authors:  X D Qu; R I Lehrer
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Characterization of Staphylococcus aureus cardiolipin synthases 1 and 2 and their contribution to accumulation of cardiolipin in stationary phase and within phagocytes.

Authors:  T Koprivnjak; D Zhang; C M Ernst; A Peschel; W M Nauseef; J P Weiss
Journal:  J Bacteriol       Date:  2011-06-10       Impact factor: 3.490

6.  The enteric nervous system neuropeptide, bombesin, reverses innate immune impairments during parenteral nutrition.

Authors:  Rebecca A Busch; Aaron F Heneghan; Joseph F Pierre; Xinying Wang; Kenneth A Kudsk
Journal:  Ann Surg       Date:  2014-09       Impact factor: 12.969

7.  Secretory non-pancreatic phopholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2.

Authors:  B Guidet; O Piot; J Masliah; V Barakett; E Maury; G Bereziat; G Offenstadt
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

8.  Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin.

Authors:  R Cholbi; M L Ferrándiz; M C Terencio; S De Rosa; M J Alcaraz; M Payá
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

9.  IL-25 improves luminal innate immunity and barrier function during parenteral nutrition.

Authors:  Aaron F Heneghan; Joseph F Pierre; Ankush Gosain; Kenneth A Kudsk
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

10.  Wall teichoic acid deficiency in Staphylococcus aureus confers selective resistance to mammalian group IIA phospholipase A(2) and human beta-defensin 3.

Authors:  Tomaz Koprivnjak; Christopher Weidenmaier; Andreas Peschel; Jerrold P Weiss
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.